Theralase Technologies Inc. (TLTFF)
OTCMKTS · Delayed Price · Currency is USD
0.1400
+0.0015 (1.11%)
Apr 24, 2025, 4:00 PM EDT

Theralase Technologies Company Description

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally.

The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ.

Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain.

The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine.

Theralase Technologies Inc. is based in Toronto, Canada.

Theralase Technologies Inc.
Theralase Technologies logo
Country Canada
Industry Medical Devices
Sector Healthcare
Employees 20
CEO Roger Dumoulin-White

Contact Details

Address:
41 Hollinger Road
Toronto, Ontario M4B 3G4
Canada
Phone 416 699 5273
Website theralase.com

Stock Details

Ticker Symbol TLTFF
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency CAD
ISIN Number CA88337V1004
SIC Code 3845

Key Executives

Name Position
Roger John Dumoulin-White B.Sc., P.Eng. President, Chief Executive Officer and Director
Kristina Hachey CPA Chief Financial Officer and Director
Dr. Arkady Mandel DSc., M.D., Ph.D. Chief Scientific Officer and Director
David M. Groves B.A President of World Trade Division
Dr. Terry Ruch DVM Equine Medical Consultant